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Adult mesenchymal stem cells (MSCs) are being investigated further for their use in stem cell therapies. However, as they are
found in very low numbers in adult tissue, expansion in vitro is required to produce desired MSC numbers for clinical application.
The need for eﬀective cell-based therapies is increasing due to a rise in the ageing population, increasing the prevalence of
musculoskeletal disorders. This review investigates how factors, age and gender of donor, as well as seeding density can aﬀect MSC
expansion. Age and gender of donor have received mixed results from studies, whereas seeding density studies have produced
consistent results for numerous MSC sources, favouring lower seeding densities. Further research is required to reduce the risk of
infection, loss of cell characterisation in cell culture, and making cell-based therapies more cost eﬀective through creating rapid
expansion of MSCs regardless of patient factors.
1.Introduction
Stem cells are an undiﬀerentiated population, capable of
endless self-renewal and diﬀerentiation down one or more
lineages to produce specialised cell types [1]. Their ability to
produce many cell types in vitro is one of the characteristics
that has highlighted their importance for use in cell-based
therapies. The earliest stem cell in the human body, the fer-
tilised egg, is totipotent and has the capacity to differentiate
into all cell types of the human body, as well as tissues to
support the embryo. As the fertilised egg develops into cells
of the human embryo, diﬀerentiation capacity down lineages
become more limited [2].
Adult stem cells, also known as somatic stem cells, are
located in many tissues of the human body and are required
to restore normal function via repair and regeneration of
tissues in vivo, for example, satellite cells in muscle tissue.
They exist in a quiescent state until activated by mediators of
injuryordisease.Adultstemcellsmakeupasmallpercentage
of cells in a tissue and are surrounded by mature cells that
havereachedtheendofthediﬀerentiationprocessanddonot
have the capacity to proliferate or diﬀerentiate [3]. The use
of adult stem cells in clinical application is being investigated
further due to restrictions and ethical issues surrounding the
use of embryonic stem cells. Adult mesenchymal stems cells
(MSCs) are suitable for use in clinical application as they
have been found to adhere well to plastic, proliferate and
differentiate well in vitro, and have suitable properties for
transplantation: low immunogenic and high immunosup-
pressive properties, due to a low or absent HLA-2 marker
on their cell surface [4, 5]. They have currently been shown
to have the potential to enhance treatment of cardiovascular
[6], neurological [7], and musculoskeletal disorders [8]b y
diﬀerentiating into cardiomyocytes and vascular cells, neu-
ron and glial-like cells, and chondrocytes, respectively.
An early study by Friedenstein et al. reported that MSCs
isolated from bone marrow, were found to be similar to
ﬁbroblasts [4, 9, 10]. These cells were clonogenic, adhered
to plastic in culture, and replicated extensively in vitro.I th a s
been demonstrated that these cells are multipotent, diﬀeren-
tiating into osteoblasts, chondrocytes and adipocytes, when
transplanted back in vivo [11, 12]. As well as the isolation of
MSCs from bone marrow, other sources including adipose
[13], skeletal muscle [14], synovium [15] and synovial fat2 Stem Cells International
pad [16] have also been reported to contain MSCs capable
of multilineage diﬀerentiation.
MSCs have shown great capabilities for use in clinical
application; however, as they are found in very low numbers
in adult tissue, expansion in vitro is required to reach the
desired numbers before their use in clinical application. We
have yet to develop a clear understanding of how to optimise
MSCexpansioneﬃciently,asmanypapershavereporteddis-
crepancies in results such as how age of donor, gender of
donor, and seeding density can aﬀect cell proliferation rate.
Factors aﬀecting optimisation of MSCs can be grouped into
patientfactorssuchasageandgender,aswellascellculturing
factors such as seeding density used. This review article will
look at how age, gender and seeding density aﬀects the pro-
liferation of adult mesenchymal stem cells.
2. Donor Age and MSC Proliferation
Mixedresultshavebeenpublishedinexistingliteratureabout
how age of donor aﬀects mesenchymal stem cell expansion
rate. Many have reported an inversely proportional relation-
ship between proliferation rate and age; however, others have
reported no relationship. Most literature has used BMSCs
when looking at the eﬀects of age, with a couple of papers
using infrapatellar fat- pad-derived stem cells.
Khan et al. investigated the proliferation rate of synovial
fatpad MSCs in two groups of patients witha mean ageof 57
and 86, ﬁnding no signiﬁcant diﬀerence in cell proliferation
between both groups at ﬁve time points (days 2, 4, 6, 8, 10)
[17]. This trend has also been supported by many papers
investigating the eﬀect of age using bone marrow-derived
mesenchymal stem cells (BMSCs). Phinney et al. found up
to 12-fold diﬀerences between patients when investigating
growth properties of BMSCs from 17 healthy patients aged
19–45 years old; however, this diﬀerence showed no cor-
relation with age of donor (P<0.05) [18]. Both Suva et al.
and Scharstuhl et al. extracted BMSCs from the neck and
shaft of femur, respectively, at the time of hip arthroplasty
[19,20].Suvaetal.reportedvariableresultsfortimerequired
to reach the ﬁrst passage, exponential cell growth, doubling
time,andmaximalcellampliﬁcation,butagainnoneofthese
variations were found to be due to age-related diﬀerences of
donors. Similarly with a sample size of 98, Scharstuhl et al.
also reported that proliferative capacity is maintained with
ageing after correlating proliferation with age.
On the other hand, Baxter et al. reported a severely
reduced proliferative capacity with slower growth rate in a
group of 59–75 years old patients compared to 0–18 years
old [21]. This was supported by other studies that found
that doubling time was almost 2-fold longer in older patients
compared to younger [22, 23]. Culturing BMSCs over 4
months from “young” (7–18 years old), “adult” (19–40 years
old), and “aged” (>40 years old) patients extracted from the
posterior iliac crest, Stolzing et al. found diﬀerences between
proliferation rate from week 5 in culture, describing that the
proliferation rate of the “aged” BMSCs began to decrease
and the growth curve started to plateau [24]. On the other
hand, BMSCs from “adult” patients continued to increase in
proliferation rate throughout the whole 4 months in culture.
The “young” group of BMSCs were only investigated over 10
population doublings, where they also displayed a pattern of
increasing proliferation rate with time. These ﬁndings were
also supported by Dexheimer et al., who found a signiﬁcant
age-related decline in proliferation rate in BMSCs from older
comparedtoyoungerpatients[25].Clonalexpandabilityalso
decreased with increasing age with cells from an 80-year-
old patient producing half the number of clones of that of
BMSCs from a 20-year-old.
Interestingly, whilst investigating the eﬀect of age on
MSC proliferation from synovial fat pad tissue, one study
explored this relationship at eight diﬀerent seeding densities:
50, 250, 500, 1000, 2500, 5000, 750, and 10000cells/cm2
[26]. Extremely varied results were found, with ﬁve seeding
densities (50, 250, 500, 5000, 7500cells/cm2) showing that
there was an age-related decline in population doublings,
whereas 10,000cells/cm2 showed an age-related increase in
populationdoublingsandtwodensities(2500and1000cells/
cm2), showed no correlation with age. Varied results even
between the same set of cells at diﬀerent seeding densities
shows that properties of MSCs and how they are altered are
not properly understood. It also shows that proliferation can
be aﬀected by many factors, in which more research needs to
go into providing knowledge about how MSCs are aﬀected
by a range of factors.
It is not known whether ageing of MSCs is due to factors
inside the cells or factors in the surrounding tissue. It has
been found that reduced synthesis of proteoglycans and gly-
cosaminoglycans in the surrounding tissue results in a re-
duced proliferation and viability of MSCs in vivo [27].
Also, the production of advanced glycosylated end products
(AGEs) inhibit proliferation of MSCs by activating apoptosis
and reactive oxygen species (ROS) production [28]. In com-
parison, Zhou et al. suggested that intrinsic factors may be
responsibleforage-relatedchangesinBMSCs[22].Hefound
that there was a 4-fold increase in the number of MSCs
that were positive for senescence-associated β-galactosidase
(SA- β-gal) and increased expression of p53 and its pathways
genes (p21 and BAX) that may be responsible for mediating
reduced proliferation potential. It has also been suggested
that the expression of p16INK4a, an inhibitor of CDK4
and CDK6 which promote proliferation, increases with age
[29]. MSCs from older patients were also found to be more
apoptotic as physiological eﬀects of ageing on MSCs induce
senescence [22].
The eﬀect of ageing on the properties of MSC remains
controversial with inconsistent results, even when using
MSCs from the same source type and patient. It is important
to investigate how age aﬀects the proliferation rate of mesen-
chymal stem cells to provide knowledge as to whether stem
cell therapies can be achieved via autologous repair for older
patients.Thisisaquestionwhichisbecomingofgreatimpor-
tance as with an ageing population, the prevalence of mus-
culoskeletal disorders is increasing. Some studies have also
shown that a higher proliferation rate is related to strong-
er osteogenic, chondrogenic, and adipogenic diﬀerentiation
potential, crucial for repair of damaged or diseased muscu-
loskeletal tissue [25] .T h ev a r i a b l er e s u l t sc o u l db ed u et oStem Cells International 3
studieshavingarestrictedagerangeduetothepatientcohort
available, studies having diﬀerent age ranges for “young” and
“old” categories, or not having a large enough sample size for
y o u n gp a t i e n t sa sq u i t eaf e ws t u d i e su s eB M S C se x t r a c t e d
during hip arthroplasties, which on average occur more fre-
quently in the older population. The variable results between
studiescallformoreworkonthissubjecttobeundertakento
get a clear idea of how age of donor aﬀects MSC proliferation
rate. In particular, diﬀerent sources of MSCs should be in-
vestigated and perhaps, if ageing is found to aﬀect MSC ex-
pansion, then one source may be less aﬀected and more suit-
ed to cell based therapies for the older population.
3. Gender and MSC Proliferation
There is little literature on the eﬀects of gender on MSC pro-
liferation potential, as the majority of papers group results
frommale and female patients together. MSC culturing tech-
niques, such as duration and concentration of collagenase,
and best harvesting site for maximal yield vary between
males and females [30, 31]. Faustini et al. using adipose-
derivedstemcells(ADSCs)discoveredthatADSCunderwent
most eﬀective digestion when adipose tissue was incubated
with 0.2% collagenase for 1 hour for males, whereas over-
night digestion was more eﬀective for tissue from females
[31]. Females having a signiﬁcantly higher yield of MSCs
than males were also reported, with females having on aver-
age2.05 ±1.46log-millioncellscomparedto1.44 ±1.62log-
millioncells from males. This, along with other knowledge
that stem cells have estrogen and androgen receptors, sug-
gests that there can be gender diﬀerences in regards to MSC
proliferation. The higher levels of estrogens in females and
androgens in males are thought to be responsible for the
diﬀerences in male and female MSCs [30]. Most studies sug-
gest that androgens have an inhibitory eﬀect on the function
of stem cells [32], whereas estrogens have an excitatory role
controlling levels of cytokines and growth factor production
in MSCs [33]. Estrogens have also been found to upregulate
the expression of receptors on embryonic stem cells (ERa
and ERb), increasing the production of 17b- estradiol which
activates MAPK and cyclin-dependant kinases (cdk), which
are intermediates in the cell cycle [34].
Despite suggestions and ﬁndings in some studies, Dex-
heimer et al. found no gender diﬀerences in MSC frequency
and expansion of nonclonal MSC populations from bone
marrow [25]. As gender could be a factor of inﬂuence for
reaching desired cell numbers, research investigating the
eﬀect of gender on the properties of MSCs needs to be un-
dertaken. This will help to make extraction and expansion
of MSCs more eﬃcient for all patients undergoing cell-based
therapies as it can be known to extract more tissue from
males than women, if females do have a higher yield as
Faustini et al. reported. Also, more work should investigate
the preferred isolation and culturing techniques for MSCs
from male and female patients to ensure that the maximum
yield of MSCs is extracted from the tissue source as
possible.
4. SeedingDensityandMSCProliferation
Although limited, the literature suggests that seeding density
doeshaveaneﬀectoncellproliferationrate.Bothetal.found
that BMSCs seeded at lower densities had a faster prolif-
eration than higher densities, with MSCs at 100cells/cm2
reaching their target of 200million cells, 4.1 days faster than
cells that were seeded at a higher density (5000cells/cm2)
[35]. Further decrease in seeding density below 100cell/cm2,
also showed a further increase in proliferation rate. A similar
relationship was found by Lode et al., when investigating
the eﬀect of seeding density on three-dimensional scaﬀolds
[36]. They found that the highest seeding density of 1 ×
106 cell/cm2 resulted in a minimal increase in cell number
compared to the lowest seeding density, which had a large
increase in cell number. Extremely low densities (0.5–
12cells/cm2) showed the size of single-cell-derived colonies
that represent cell number and hence proliferation rate, to be
inverselyproportionaltoseedingdensity[37].Anotherstudy
looking at four diﬀerent seeding densities for BMSCs also
had results that were consistent with the previous ﬁndings.
After 10 days in culture, BMSCs seeded at 2500, 250, 25, and
2.5cells/cm2 had mean results of 2.72 ± 0.48, 4.8 ± 0.42,
6.7 ± 0.53, and 7.6 ± 0.97 population doublings, showing
that cells at a lower density have a faster proliferation rate
than those of a higher density. Signiﬁcant gain in population
doublings was seen between 2500 and 250, as well as 250
and 25 (P<0.05). On the other hand, although more
population doublings occurred at lower densities, there was
no signiﬁcant diﬀerence between using 25 and 2.5cell/cm2.
They also showed that seeding density did not aﬀect cell
characterisation as all cells had the same cell surface marker
characterisation proﬁles [38]. This trend has been shown
to occur in MSCs from various tissue locations not only
bone marrow, conﬁrming that seeding density does have a
significant eﬀect on proliferation rate. A study was carried
out by Mochizuki et al. exploring the optimum seeding den-
sity for bone marrow-, synovium-, periosteum-, adipose-,
and skeletal muscle-derived mesenchymal stem cells. Mea-
suring cell growth and colony formation using crystal violet
staining, they found that all MSCs had a greater colony size
at lower seeding densities compared to higher; for example,
MSCs derived from synovial tissue showed smaller colony
size or cells became indistinct after 14 days when seeded
at 105 and 106 cells/60cm2, compared to seeding densities
of 103 or 104 cells/60cm2. Results showed that all sources
had an optimum seeding density of 103 or 104 cells/60cm2or
103/104 cells per cm2 for BMSCs. In addition similar trends
were seen when cells were seeded at 50cells/cm2 producing
a higher cumulative number of cells than at 5,000cells/cm2.
They also suggested that seeding density and total cell
doubling times can aﬀect senescence of cells. Synovial fat-
pad derived MSCs observed results that were consistent with
those from BMSCs [39].
The lower growth rate of cells seeded at higher densities
could be due to contact inhibition. Higher growth rates at
lower densities have been explained by the presence of small
and agranular cells, also referred to as recycling stem cells,
in the lag phase, which gave rise to large cells during the log4 Stem Cells International
phase of exponential growth [37]. The log phase has been
found to last for a longer duration in cells seeded at lower
densities, and hence more population doublings occur due
to a longer exponential growth phase [40]. Higher growth
potential at lower seeding densities may also be due to more
availability of nutrients per cell.
Finding the optimum seeding density for maximal ex-
pansion is useful in both laboratory investigations as well as
potential clinical applications as the cell culturing procedure
canbelesstimeconsuming,decreasingtheriskofcellculture
contamination, infection or loss of characteristics in cell
culture,inadditiontomakingtheprocessmorecosteﬀective.
These studies show that rapid expansion to reach a suﬃcient
number of cells for clinical applications can be achieved
by using lower seeding densities. As numerous papers have
f o u n dt h a tM S C sf r o mar a n g eo fs o u r c e sa l lh a v eaf a s t e r
proliferation rate/population doublings at lower seeding
densities, if consistent relationships are found between age
of donor and proliferation rate or gender and proliferation
rate,thenperhapsseedingdensitycanbeusedtocompensate
for and be used to speed up expansion of MSCs for clinical
application.
This review has looked at how some factors such as age
andgenderofdonoraswellasseedingdensitycanaffectMSC
expansion for clinical application. Whilst studies disagree on
the eﬀects of ageing on MSCs, more work should be carried
out to explore the eﬀect of age on numerous MSC sources
in the hope that a consistent relationship can be found.
Identiﬁcation of relationships will enable cell culturing tech-
niques to be adapted for expansion of MSCs from particular
age groups of patients, without increased risk of infection in
cell culture by minimising time spent in culture. Gender is
also a factor that should be investigated fully, as exposure to
diﬀerent concentrations of hormones may alter properties of
MSCs. Research of how age and gender aﬀects MSC prolif-
eration should make sure that apart from the factor being
investigated patients are all matched by gender, age, social
factors, medical history, and chronic illness to ensure that all
results are not due to potential confounders. In comparison,
seeding density has shown consistent results over numerous
s t u d i e sa sw e l la sf o rn u m e r o u sM S Cs o u r c e s .A st h er e -
lationship between seeding density and proliferation rate of
MSCs has been found, once age and gender relationships are
also investigated, seeding density could perhaps be used to
compensate for the eﬀect of patient factors to result in rapid
expansion of MSCs.
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